First Manhattan’s Checkpoint Therapeutics CKPT Stock Holding History

First Manhattan’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-100	Closed	-$1K	–	1707
2022 Q3	$1K	Buy	+100	New	+$1.19K	﹤0.01%	1456

Other funds holding CKPT

TwinBeech Capital Purchase, New York $965M AUM 0.23% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAM

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

PAS

Park Avenue Securities New York $16B AUM 26.77% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

First Manhattan's CKPT Position: Q4 2022 in Review

First Manhattan sold out of Checkpoint Therapeutics (CKPT) in Q4 2022, closing a stake of 100 shares — an estimated $1K sold.

First Manhattan first reported a position in CKPT in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 40 funds tracked by Wall St. Rank hold CKPT as of Q4 2022.

First Manhattan reported no remaining Checkpoint Therapeutics position as of Q4 2022 after selling out during the quarter.
First Manhattan sold 100 Checkpoint Therapeutics shares in Q4 2022, an estimated $1K.
First Manhattan first reported a position in Checkpoint Therapeutics in Q3 2022 and held it in 1 quarter.
First Manhattan's Checkpoint Therapeutics position peaked at $1K in Q3 2022.
40 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q4 2022.

Based on First Manhattan's 13F filing for Q4 2022, filed 14 Feb 2023.